Essential Pharma gains neuroblastoma candidate through Renaissance buy
Phase 2License out/inClinical ResultImmunotherapyAcquisition
Essential Pharma announced on Tuesday that it acquired Renaissance Pharma for an undisclosed sum, gaining the latter's immunotherapy candidate, dubbed Hu14.18, which is in Phase II development for the treatment of high-risk neuroblastoma.
"Our acquisition of Hu14.18, the group's second product for treatment of a rare disease, and the first development-stage asset in our portfolio, is a significant milestone," remarked Essential CEO Emma Johnson. Hu14.18 "has already produced positive data in Phase II clinical trials, demonstrating a significant improvement in survival, and we are now committed to developing this immunotherapy to be able to bring it to market."
A Phase II trial incorporating Hu14.18 into first-line therapy and within post-consolidation therapy for patients with high-risk neuroblastoma showed positive patient outcomes with 73.7% three-year event-free survival and 86% overall survival (OS). The trial is approaching the five-year OS readouts.
Under the deal, Renaissance CEO Simon Ball will continue to work with Essential on the development of Hu14.18, as will many of the Renaissance team. Essential will work with St Jude Children’s Hospital in accordance with their 2023 exclusive license agreement to drive the development and commercialisation of Hu14.18 across the territories licensed to Renaissance. Essential will be responsible for clinical development of Hu14.18 along with defining the optimal route for regulatory approval and commercial launch of the immunotherapy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.